Recent advances in nanotechnology have enabled the synthesis and characterization of nanomaterials suitable for applications in the¯eld of biology and medicine. Due to their unique physicochemical properties, carbon-based nanomaterials such as fullerenes, metallofullerenes, carbon nanotubes and graphene have been widely investigated as multifunctional materials for applications in tissue engineering, molecular imaging, therapeutics, drug delivery and biosensing. In this review, we focus on the multifunctional capabilities of fullerenes and metallofullerenes for diagnosis and therapy. Speci¯cally, we review recent advances toward the development of fullerene-and metallofullerene-based magnetic resonance imaging (MRI) and X-ray imaging contrast agents, drug and gene delivery vehicles, and photodynamic therapy agents. We also discuss in vitro and in vivo toxicity, and biocompatibility issues associated with the use of fullerenes and metallofullerenes for biomedical applications.
Introduction
The development of tools such as electron and scanning probe microscopes, 1, 2 and the discovery of nanomaterials such as fullerenes 3 and quantum dots 4 in the 1980s galvanized scienti¯c progress in the¯eld of nanotechnology. Today nanotechnology is an exciting interdisciplinary¯eld that could signi¯cantly revolutionize technologies for diverse applications, ranging from electronics and telecommunication, to energy and healthcare. Nanomaterials, generally in the range 1À100 nm (in at least one dimension), exhibit unique mechanical, electrical and optical properties compared to micro-or macro-sized materials. For example, carbon nanotubes possess a Young's modulus of $ 1 TPa ($ 5 times greater than steel), and are highly conductive with current densities at $ 6 Â 10 7 A cm À2 ð$ 100 times greater than metallic conductors such as copper). 5À7 Using various \top-down" and \bottom-up" approaches such as chemical vapor deposition (CVD), 8 chemical etching, 9 electrospinning, 10 self-assembly, 11 photolithography, 12 electron beam lithography 13 and thin¯lm deposition; 14 nanomaterials can be synthesized from metals, 15 ceramics, 16 semiconductors, 17 polymers, 18 organic carbon-based materials, 19 organic-inorganic hybrid materials,nanomaterials 22 in a variety of morphologies such as tubes, platelets, ribbons,¯bers, wires, rods, horns, shells,¯lms and particles. 8,12,23À26 Various covalent and noncovalent functionalization strategies have been formulated for the attachment of ligands and molecules toward development of nanomaterials suitable for biomedical applications such as molecular imaging and targeted delivery, and to mitigate nanomaterial toxicity. 27 Carbon nanostructures such as fullerenes, metallofullerenes, carbon nanotubes and graphene are the most widely researched class of materials. They show remarkable physicochemical properties, and functionalization capabilities that can be harnessed for the next-generation biomedical applications. Indeed, they have been extensively investigated for applications such as imaging probes for cellular labeling and tracking, 28À31 reinforcing agents for polymeric nanocomposites, 21,32À34 substrates for cellular proliferation and di®erentiation 35À38 and drug and gene delivery agents. 39À42 The¯rst studies investigating the potential of carbon nanomaterials for biomedical applications were performed on fullerenes and metallofullerenes (see Table 1 for various biomedical applications of fullerenes and metallofullerenes). 43 There are now multiple reviews that document advances in the functionalization, physicochemical properties and material science applications of either fullerenes or metallofullerenes. 44À47 Some recent reviews also focus on biomedical applications of fullerenes or metallofullerenes. 46 ,48À51 This review seeks to complement these existing publications, and focuses on recent advances in the development of fullerenes and metallofullerenes as multifunctional platforms for diagnostic and therapeutic applications. Speci¯cally, we review the published literature on fullerenes and metallofullerenes as magnetic resonance imaging (MRI) and X-ray imaging contrast agents, drug and gene delivery vehicles and photodynamic therapy (PDT) agents. Also, reviewed are pertinent in vitro and in vivo toxicity and biocompatibility issues related to these carbon nanomaterials.
We conducted a comprehensive search in the database of US National Library of Medicine, National Institutes of Health (PubMed, www.ncbi. nlm.nih.gov). Relevant articles that focus on in vitro and in vivo studies of fullerenes and metallofullerenes for imaging, drug and gene delivery and therapeutic applications were identi¯ed using the Toth et al. 59 Shu et al. 68 Iodinated fullerenes X-ray imaging contrast agents Wharton and Wilson 77 Amphiphilic fullerenes (buckysomes, PEBs) Drug delivery Partha et al. 96, 97 Fullerene-paclitaxel Zakharian et al.
53
Fullerene-peptide conjugates Dermal drug delivery Rouse et al. 100, 112 Fullerene-DOX conjugates Drug delivery and radical scavenging Injac et al.
92,93
Chaudhuri et al. 94 Liu et al. 95 
Fullerenols
Antioxidants and radical scavenging Gharbi et al.
125
Fullerene polyamine (tetra amino fullerenes) Gene delivery, transfection Isobe et al.
104,105
Nakamura et al. 106, 108 Amino-fullerene adducts Nonviral gene delivery Sitharaman et al.
103
Hydrophobic or cationic fullerenes PDT Mroz et al. 81, 86 Fullerene malonic acid adducts Rancan et al.
82
PEG modi¯ed fullerenes Tabata et al. 88 Porphyrin-C 60 dyads Alvarez et al. 85 Milanesio et al. We systematically screened published articles included in this review. The search resulted in 34 articles for MRI contrast agents, 8 for X-ray contrast agents, 75 for drug and gene delivery, 69 for PDT and 72 for in vitro and in vivo toxicity. Fulltext experimental studies were considered and evaluated independently by each author. Only publications in English with an experimental group sample size ! 5 were considered. The minimal group size of n ¼ 5 was chosen to avoid inclusion of studies containing low sample sizes since studies were based on varying methods and treatment conditions.
Bioimaging
Current medical imaging modalities such as MRI and X-ray computed tomography (CT) possess unique strengths and weaknesses. Signi¯cant research has been devoted towards developing the next generation of contrast agents for these modalities. Contrast agents are compounds administered to improve the sensitivity and diagnostic con¯dence of these modalities for various pathologies and diseases. The contrast enhancement mechanism for each of these modalities is di®erent. The contrast seen in MRI is due to the concentration and magnetic properties of water protons, while CT contrast is due the attenuation of X-rays transmitted through the patient. The multifunctional capabilities of metallofullerenes have been harnessed by encapsulating atoms within its hollow interior space, which modulate water protons, the source of signal during MRI, or interact with X-rays in CT. Furthermore, these nanoparticles can accumulate in the diseased tissue due to enhanced permeability and retention properties, and can be covalently or noncovalently functionalized with suitable moieties to improve their blood circulation half-life and tissue targeting capabilities. 50À53 
MRI contrast agents
MRI is one of the central diagnostic technique used for medical imaging in the clinic. Annually, contrast agents are administered in $ 18 million MRI procedures worldwide to improve diagnostic con¯-dence. 54 The two predominant types of MRI contrast agents are T 1 and T 2 agents that decrease longitudinal and transverse relaxation times, respectively. Relaxivity (expressed in mM À1 s À1 Þ is the measure of contrast agent e±cacy that accelerates the relaxation process of water protons. The most widely used ($ 99% of MRI procedures) clinical T 1 contrast agents are metal ion-based chelate complexes of transition elements such as Gd 3þ and Mn 2þ . 55, 56 Recent theoretical and experimental studies show that relaxivity values of these contrast agents are suboptimal, and predict the development of contrast agents with $ 50À100 times greater relaxivity. 50, 57 Gd 3þ ions possess a large magnetic moment ( 2 ¼ 63 2 B ), and symmetric electronic ground state ( 8 S 7=2 Þ, permitting Gd 3þ ion-metal chelate complexes to be used as MRI contrast agents. Over the last decade, Gd 3þ -based carbon nanostructure complexes were developed that have signi¯cantly higher relaxivity values than clinically used Gd 3þ -based contrast agents. Water-soluble endohedral metallofullerenes encapsulating Gd 3þ ions (a.k.a. gadofullerenes, see Fig. 1 for representative structural depictions) have relaxivity values $ 2À20 times higher than clinically used gadolinium-based contrast agents. 29, 50 ,58À66 These increased relaxivity values are attributed to interactions of a large number of water protons with Gd 3þ ion via the fullerene cage. Results suggest an entirely outer-sphere relaxation mechanism with largest outer-sphere relaxivities reported for a Gd 3þ -based MRI contrast agent. Additionally, it has been hypothesized that a fullerene molecule that encapsulates Gd 3þ ion shields and limits in vivo dissociation of Gd 3þ ion, thereby signi¯cantly reducing toxicity concerns. Long-term in vitro and in vivo stability studies are still needed to test this hypothesis.
The propensity of water-soluble gadofullerenes to aggregate in solution, and the dependence of this aggregation on pH and salts present in biological media are the main factors responsible for the large variation in the relaxivity of gadofullerenes-based MRI contrast agents. 59,65,67À69 In vitro studies show that decreased pH (from alkaline to acidic pH values) of water-soluble gadofullerenes solutions increases their aggregation. This increased aggregation, in turn, increases the relaxivity of gadofullerenes making them promising candidates for monitoring and mapping pH changes in diseased tissues (e.g., tumors) by MRI. 59 In vivo studies are needed to validate the capabilities of gadofullerenes as pH-responsive MRI contrast agents. A di±culty in testing this hypothesis lies in the opposing e®ect of biologically relevant salts on gadofullerene relaxivity. 65, 66 Studies show that the relaxivity of gadofullerenes decreases (e.g., r 1 of Gd@C 60 (OH) x decreases from 83.2 mM À1 s À1 to 43.1 mM À1 s À1 Þ in biological bu®ers such as phosphate-bu®ered saline (which contains sodium, chloride and phosphate ions) in comparison to salt-free gadofullerene solutions. 65, 66 This decreased relaxivity is attributed to disaggregation of gadofullerene aggregates due to the presence of salts. 65, 66 In vitro studies were conducted to test the e±-cacy of gadofullerenes as magnetic labels for cellular MRI. Anionic gadofullerenes such as Gd@C 60 [C (COOH) 2 ] 10 , internalized by mesenchymal stem cells (MSCs) within 2À8 h of incubation (see Fig. 2 ) and intercalated within the cell membrane, maintaining a stable intracellular Gd 3þ concentration (eliminating the possibility of Gd 3þ leaching). 29 In vitro cellular toxicity and viability assays indicate no cellular damage and $ 300% increase in the T 1 weighted MRI signal intensity from gadofullerenelabeled MSCs (compared to controls: MSCs labeled with Magnevist r ). These results suggest potential application of gadofullerenes for in vivo stem cell tracking applications via MRI, a highly desirable property for tissue engineering and regenerative medicine applications.
In vivo biodistribution of Gd@C 60 [C(COOH) 2 ] 10 tracked via MRI after administration to rodents (35 mg/kg, tail vein) showed increased uptake of the gadofullerene derivative in kidney, with minimal uptake in liver. 64 MRI of kidneys showed $ 50% increase in contrast within 16 min after injection. Accumulation and excretion of Gd@C 60 The development of a tri-metallic-nitride templating method to encapsulate multiple metal ions by Dorn and coworkers led to a protocol for encapsulation of multiple Gd 3þ ions inside the fullerene cage. 71 Referred to as`Hydrochalarones' (trimetallic nitride fullerene, Gd 3 N@C 80 Þ, these are thermally and chemically stable derivatives of gadofullerenes (cage decomposition $ 500 C, resistant to structural damage upon heating in concentrated nitric acid). 61 The¯rst in vivo studies assessing the potential of Gd@C 82 (OH) n as MRI contrast agent were performed by Sinohara and coworkers in 2001. 63 Gd@C 82 (OH) n was administered to female CDF1 mice (female, 8 weeks old) intravenously at a dose of 5 mol Gd/kg, 20 times lower than the clinical dose of Gd-DTPA (100 mol Gd/kg). T 1 weighted MRI images showed localization of Gd@C 82 (OH) n in reticulo-endothelial system (RES) organs such as liver, spleen and lungs after 30 min of injection. Biodistribution studies conducted to measure the concentration of gadolinium ion (via ICP analysis) in dissected organs matched the RES uptake trend, suggesting that polyhydroxylated Gd@C 82 (OH) n possess potential for development as RES-speci¯c MRI contrast agent.
In another study, polyhydroxylated PEG-Gd 3 N@C 60 administered via convection enhanced delivery to the extracellular space of rat brain tumors; (glioma tumor models, female Fisher 344 rats) demonstrated prolonged tumor retention via T 2 -weighted MR imaging. 72 Compared to controls (gadodiamide, commercial MRI contrast agent), which are cleared from the injection site within 3 h of administration, polyhydroxylated PEG-Gd 3 N@C 60 show prolonged retention in the tumor (up to 5 days post-administration). Due to the high relaxivity values of polyhydroxylated PEG-Gd 3 N@C 60 , enhanced tumor uptake, and retention, their required concentration can be signi¯cantly reduced ($ up to 40 fold reduction compared to gadodiamide) and still display adequate contrast for clinical evaluations.
X-ray imaging contrast agents
X-ray imaging is one of the most commonly used clinical imaging modalities. Image formation depends upon the attenuation of X-rays from tissues and organs, which is directly dependent upon tissue density and thickness. Dense organs such as bone can be easily visualized via radiography, but soft tissues and organs with similar densities possess similar attenuation properties, resulting in poor X-ray contrast; this limits the use of X-ray imaging to visualize soft-tissues or neo-vasculature in Multifunctional Fullerene-and Metallofullerene-Based Nanobiomaterials regenerated/newly formed tissues and organs. Therefore, contrast agents (generally iodine-based) are administered to increase X-ray contrast of soft or vascular tissues. Although iodinated contrast agents are usually safe and reports indicating serious adverse e®ects are rare (out of 61000 patients, 2.3% reported adverse events); 73 they still have potential to cause adverse e®ects. Patients have 20À30% risk of contrast media-induced nephropathy (due to tubular cell damage and resultant reduction in renal perfusion) and allergic reactions. 74, 75 Thus, development of an X-ray contrast agent with superior performance and decreased risk of nephrotoxicity would be bene¯cial.
Diamagnetic endohedral metallofullerenes encapsulating metal ions, for example, trimetallic nitride fullerenes (Lu 3 N@C 80 Þ, synthesized via trimetallic nitride template method have been reported as X-ray contrast agents. 76 In comparison to pristine C 60 containing Te°on blocks, X-ray imaging of Te°on blocks deposited with Lu 3 N@C 80 exhibit sharp X-ray contrast. In another study, highly iodinated fullerenes (containing six iodine atoms and eight acetal-protected alcohols per fullerene cage) were synthesized using a modi¯ed Bingel reaction. 77 ,78 X-ray imaging of iodinated fullerenes at concentrations of $ 150 mg I/mL, performed using standard Kodak¯lm (MIN R 2000), showed X-ray attenuation comparable to commercially used compound Iohexolr. 78 Polyhydroxylated endohedral metallofullerenes encapsulating multiple heavy metal ions (one or two ions of lutetium (Lu) , erbium (Er), dysprosium (Dy), europium (Eu) and gadolinium (Gd) encapsulated into C 82 Þ were dissolved in water at maximum stable concentrations and CT was performed using a multidetector CT scanner. 79 The CT measurements (in Houns¯eld Units (HU)) were 23.3 HU for Lu 2 @C 82 (OH) 40 40 . Although metallofullerenes encapsulating heavy metal ions possess CT numbers comparable to clinically used X-ray contrast agents, signi¯cant work (for e.g., in vivo preclinical toxicity and biodistribution studies) still needs to be performed to assess safety and e±cacy.
Therapeutics
Carbon nanoparticle-based therapeutics has several advantages over conventional therapy. Here, intrinsic physical properties of fullerenes and metallofullerenes can be harnessed for various therapeutic applications. For example, fullerenes and metallofullerenes are strong absorbers of visible light, and generate cytotoxic reactive oxygen species (ROS) that induce cell death, a property exploited for PDT applications. Furthermore, various therapeutic agents can be attached via covalent and noncovalent functionalization to the exterior carbon sheath of fullerenes and metallofullerenes along with targeting ligands to improve biocompatibility, and impart sitespeci¯c delivery capabilities. For example, fullerene sheath can be chemically derivatized to bind to chemotherapeutic drugs such as doxorubicin and cyclophosphamide (CPA), and functionalized to increase the water solubility by À stacking. 39 Additionally, fullerenes functionalized with cationic groups can serve as vectors for nonviral gene delivery applications.
Photodynamic therapy
PDT employs nontoxic photosensitive molecules capable of absorbing visible light to produce highenergy triplet states for cellular therapy. In this minimally invasive approach, photosensitizers in the presence of visible light produce cytotoxic ROS that impair cellular machinery causing cell death, eventually leading to tissue destruction. Watersoluble functionalized fullerenes, upon photoirradiation, become excited and transition to a short-lived singlet electronic state ( 1 C 60 Þ, lose energy due to°uorescence and intersystem coupling, and are converted to the long-lived stable triplet electronic state ( 3 C 60 Þ. The excited triplet state interacts with molecular oxygen forming ROS such as hydroxide (OHÁ) and superoxide anion (O 2 Á) radicals. Reaction of ROS with cellular components such as proteins, nucleic acids and unsaturated lipids causes oxidative damage, inducing cell death via apoptosis. 80 Fullerenes have been used in PDT for the destruction of viruses, microbes and cancer cells, in vitro and in vivo. 81 Phototoxicity of dendritic C 60 mono-adducts and malonic acid conjugated C 60 trisadducts, studied on jurkat cells showed $ 19% increase in cell death upon irradiation with UV light after 2 weeks of incubation. 82 C 60 tris-adducts showed phototoxicity upon irradiation with visible light whereas mono-adducts exhibited toxicity in the absence of light. In another study, fullerenes
Sitharaman inhibited the growth of HeLa cells upon irradiation with low energy visible light (6-W°uorescent light bulb, two times a day for 1 h each) by inducing ROS-mediated cleavage at guanine bases in the DNA. 83 Metal complexes of C 60 -porphyrin hybrids (ZnP-C 60 Þ produce singlet oxygen species ( 1 O 2 Þ upon photoirradiation, inducing $ 80% cell death (after 15 min of light exposure) upon incubation with human larynx carcinoma cells (Hep-2) at concentrations less than 1 M (see Fig. 4 (a) for representative structure of P-C 60 complex). 84, 85 The generated singlet oxygen species induce caspase-3 activation, releasing caspase-activated DNase (CAD) resulting in apoptosis via DNA fragmentation. C 60 -pyrrolidinium mono-adducts (compared to C 60 -pyrrolidinium tris-adducts) exhibit increased phototoxicity in murine cancer cells (CT26) after 24 h of incubation, measured by a°uorescence caspase activity-based assay using an intracellular ROS probe (H 2 DCFDA). 86 Cells incubated with C 60 -pyrrolidinium mono-adduct (2 M in RPMI media for 24 h) and H 2 DCFDA, subjected to photoirradiation by a 5 J/cm 2 405 nm laser, exhibit increased°uorescence intensity compared to controls incubated with H 2 DCFDA in the absence of fullerene adducts (see Figs. 4(e) and 4(f) for changes in the°uorescence intensity). These results suggest high PDT e±cacy of C 60 -pyrrolidinium complexes suitable for apoptotic death of cancerous cells.
Several in vivo fullerene-based PDT studies have been published. 87, 88 Hybrid MRI-PDT systems based on PEG conjugated C 60 -Gd 3þ -DTPA complexes (diethylenetriaminepentaacetic acid) exhibit increased PDT and improved MRI contrast (compared to Magnevistr controls) following intravenous administration to tumor bearing mice, suggesting potential for theragnostic applications that allow simultaneous monitoring of tumor
. 87 The MRI contrast for PEGconjugated C 60 -Gd 3þ -DTPA complex reached its peak after 3 h of administration and was sustained up to 24 h. Magnevistr controls showed increased contrast for only 1 h. In another study, prolonged in vivo retention of PEG conjugated C 60 resulted in increased PDT activity and suppression of subcutaneous tumor growth. 88 C 60 -PEG conjugates were injected intravenously (6 mg PEG-C 60 conjugate at 424 g/kg C 60 dose) and exposed to light (89.2 mW/ cm 2 , 400À505 nm) 24 h post-injection. For comparison, aqueous glucose solution containing Photofrin (80 g/mL, 4 mg/kg injection, 72.5 mW/cm 2 , 610À800 nm) was used as a positive control, and PBS injection was used as a negative control. Tumor volume ratio (ratio between the volume of tumor before and after 11 days of light exposure) was 10:2 AE 2:23 for PBS controls and 0:54 AE 0:05 for C 60 -PEG conjugate, suggesting high e±cacy of C 60 -PEG conjugates for PDT of tumors. Histological analysis showed tumor necrosis without damage to the overlying skin tissue. 88 
Drug and gene delivery
Fullerene-based systems for delivery of drugs and genes possessing selective tissue targeting, and with controlled release capabilities have been developed. 89, 90 Water-soluble fullerenes can successfully pass through the cell membrane and serve as intracellular delivery agents. 90, 91 To mitigate oxidative damage to cells and tissues, polyhydroxylated fullerenes (a.k.a. fullerenols), with radical scavenging ability, have been used to deliver doxorubicin (DOX), a widely used chemotherapeutic drug. Fullerenol [C 60 (OH) 24 ], administered in a rat colorectal cancer model (25 mg/kg/week, 50 mg/kg/week and 100 mg/kg/week for 3 weeks in male Wistar rats) protected liver and heart from DOX-induced oxidative damage (1.5 mg/kg/week for 3 weeks) (see Fig. 5 ). 92 In another study, the e®ects of chronic DOX toxicity were mitigated by exploiting the radical scavenging abilities of fullerenols [C 60 (OH) 24 ]. Proof-of-principle in vivo studies were performed on Sprague Dawley rats. 93 Fullerenols were injected at 100 mg/kg 30 min before DOX injection (8 mg/kg). Fullerenols reduced the elevated neutrophil count (from $ 58% for DOX treatment groups to $ 52% for DOX-fullerenol group). Additionally, results showed $ 37% reduction in the level of LDH (a marker of cardiovascular damage), compared to free DOX group past fullerenol administration.
Water-soluble, covalently crosslinked DOX-PEG-C 60 conjugates, capable of high therapeutic loading of DOX and time-dependent DOX release, were evaluated for cytotoxicity against metastatic human breast cancer cells (MDA-MB-231), mouse melanoma cells (B16-F10) and mouse lung carcinoma cells (LLCC1). 94 Results showed a time-dependent increase in cytotoxicity of DOX-PEG-C 60 conjugates against all cell lines (apoptosis due to G2-M phase block). LC 50 values for C 60 
-DOX conjugates
Multifunctional Fullerene-and Metallofullerene-Based Nanobiomaterials 6 ). 95 Two-photon imaging of internalized DOX conjugate using a femtosecond pulsed (900 nm) laser con¯rmed cellular uptake of DOX-PEG-C 60 conjugate. Since DOX can be excited using two photons at wavelengths in the near infrared region of the spectrum, DOX-PEG-C 60 can be used for cellular imaging as an intracellular two-photon°u orescence probe. C 60 -paclitaxel conjugates [see Fig. 7 (a) for representative structure], forming stable liposomes with dilauroylphosphatidylcholine (DLPC), suitable for aerosol-based delivery to lungs, exhibited cytotoxicity against human epithelial lung carcinoma cells (A549).
53 C 60 -paclitaxel-DLPC liposomes (2.77 m in diameter, as measured by dynamic light scattering) were incubated with A549 cells for 1 h at an equivalent paclitaxel concentration of 12.5 M. Cell culture media was replaced 1 h after treatment and plates were incubated for an additional 2 days. The mean IC 50 value for C 60 -paclitaxel-DLPC liposomes was 410 nM, whereas paclitaxel-DLPC control was 253 nM, suggesting similar drug delivery e±ciency of paclitaxel loaded C 60 -DLPC liposomes compared to paclitaxel-DLPC control.
Buckysomes, macroscopic structures of selfassembled fullerenes containing dendritic and fatty acid side chains, self-assemble to form nanometersized vesicles. Paclitaxel embedded buckysomes Multifunctional Fullerene-and Metallofullerene-Based Nanobiomaterials
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[PEBs, Fig. 7(b) ] exhibit signi¯cantly increased tumor drug delivery, leading to decreased infusion times, thereby enhancing anticancer e±cacy of paclitaxel. MCF-7 cells incubated with varying concentrations of PEBs (28.6 ng/mL, 143 ng/mL and 714 ng/mL of paclitaxel in PEBs) for 48 h and 72 h showed reduction in cell viability (compared to empty buckysomes) as analyzed by Trypan Blue assay. Cell viability for PEBs containing 714 ng/mL paclitaxel was comparable to that of the clinical chemotherapeutic agent Abraxane r . Preclinical investigations using pig models are underway to test PEBs as chemotherapeutic drug delivery agents. 96, 97 Fullerenes have also been investigated for the delivery of drugs like CPA. Therapeutic e±cacy of nitroxide methanofullerenes (NMFs) was evaluated for leukemia P-388 in tumor bearing BDF 1 mice. 
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NMFs administered individually (50 mg/kg and 200 mg/kg, single dose, subcutaneous injection) did not result in the suppression of tumor growth (death of all 10 animals); however, administration in conjunction with CPA (CPA þ NMF ¼ 30 þ 50 mg/kg and 30 þ 200 mg/kg, single dose, subcutaneous injection) resulted in 30% and 70% survival rates for each treatment groups, respectively. 98 These results suggest that NMFs can be administered with chemotherapeutic drugs such as CPA to improve e±cacy.
In addition to the delivery of chemotherapeutic drugs as discussed above, few studies report the use of fullerenes for potential drug delivery applications Multifunctional Fullerene-and Metallofullerene-Based Nanobiomaterials to skin, heart and hydrophobic tissue such as liver. 99À102 Functionalized fullerenes have been extensively investigated for exogenous DNA and gene delivery applications. Using HirschÀBingel chemistry, water-soluble derivatives of fullerenes were synthesized, and reported as e±cient gene delivery vectors. 103 Octa-amino derivatized C 60 and dodeca-amino derivatized C 60 were mixed with GFP plasmid solution and incubated with NIH 3T3 mouse¯broblasts and HEK 293 cells at 10 g/ mL DNA concentration for 2 h, 8 h, 24 h or 48 h. Octa-and dodeca-derived amino-fullerenes exhibited 28% and 31% transfection e±ciencies, respectively, in NIH 3T3 cells. Cytotoxicity studies show > 50% cell viability for both octa-amino and dodeca-amino fullerene complexes at 10 g/mL treatment concentration. Nakamura and coworkers performed pioneering studies on the development of functionalized fullerenes for in vitro and in vivo gene delivery.
104À107
Exogenous GFP labeled fullerene DNA complexes were internalized by COS-1 cells via phagocytosis. 106 Fluorescence imaging after 2 days of incubation displayed GFP expression, con¯rming the stability and activity of DNA-fullerene conjugates (see Fig. 8 ). 106 Transfection e±ciency for C 60 -DNA complex was 26%, comparable to 33% achieved by Transfectamr (commercially available transfection agent). In another study, tetra-amino fullerenes with strong DNA binding a±nity were investigated as transfection vectors for mammalian COS-1 cells. 104 Plasmid vector DNA (4À40 kbp) loaded onto C 60 exhibited GFP expression even after 12 days of transfection. Compared to Lipofectinr reagent which showed 0.039% transfection e±ciency after 2 weeks of culture, C 60 -DNA conjugates exhibited a transfection e±ciency of 0.73%, signi¯-cantly greater than lipofection-based transfection.
Amino-fullerenes possess signi¯cant advantages over other transfection vectors. For e±cient cellular internalization, micro-and nano-aggregates of amino-fullerene DNA complexes can be controlled Cationic amino-fullerene derivatives such as tetrapiperazino fullerene epoxide (TPFE) are reported to be resistant to endonuclease digestion and therefore can release the bound DNA inside cells for e±cient transfection. 108 In vitro gene delivery using TPFE as an arti¯cial vector was examined by adjusting various parameters such as fullerene/base pair ratio, plasmid DNA concentration and transfection time. TPFE vectors showed more than fourfold increase in transfection e±ciency compared to commercially available lipofectin-based delivery systems. TPFE e±cacy for in vivo gene delivery applications has been examined by delivering enhanced green°uorescent protein (EGFP) to pregnant ICR mice (intravenous injection, 24 g plasmid DNA in 300 L injection volume). 108 When animals were euthanized 24 h post-injections, TPFE vectors exhibited distinct organ selection and increased expression of EGFP in liver and spleen (see Fig. 9 ). TPFE vectors were nontoxic to liver and kidneys in comparison to lipofectin vectors, the use of which resulted in increased BUN concentration and liver enzymes ($ 61% increase in AST and $ 108% increase in ALT compared to TPFE groups). Furthermore, TPFE vectors could also successfully deliver insulin-2 gene to female C57/ BL6 mice, increasing plasma insulin levels and reducing blood glucose levels (compared to naked DNA controls) at 12 h post-injection (intravenous injection, 24 g plasmid DNA in 300 L injection volume).
Toxicology and Pharmacological
Studies (In Vitro and In Vivo)
Evaluation of cyto-and biocompatibility is necessary to fully develop any new material for in vivo biomedical applications. Additionally, in the future, Multifunctional Fullerene-and Metallofullerene-Based Nanobiomaterials use of these carbon nanomaterials for a wide range of commercial materials science applications will increase the risk of their release into the environment. Thus, evaluation of the in vitro cytotoxicity and in vivo toxicology and pharmacology of fullerene and metallofullerene formulations is necessary. 109 After 24 h of incubation, $ 3 orders higher cytotoxicity was observed for all cells treated with nano-C 60 compared to C 60 (OH) n . ROSmediated cell death was observed in cells exposed to nano-C 60 whereas DNA fragmentation was observed following C 60 (OH) n exposure. Addition of an antioxidant (N-acetylcysteine) inhibited ROS-mediated damage thereby reducing nano-C 60 induced toxicity, whereas addition of a caspase inhibitor (z-VAD-fmk, 0.05 M) inhibited caspase-mediated DNA fragmentation, reducing C 60 (OH) n induced cytotoxicity by 40% (compared to absence of z-VAD-fmk).
In vitro cytotoxicity
Appropriate surface functionalization strategies can signi¯cantly reduce fullerene toxicity. In comparison to pristine fullerenes (C 60 Þ, watersolubilized derivatives (C 60 (OH) 24 , Na 12À15 ] ð2À3ÞÀ and C 3 Þ exhibit $ 7 fold decrease in cytotoxic response upon incubation with human dermal¯broblast cells (HDF) at various concentrations, for 48 h, measured using LIVE-DEAD and LDH assays (see Fig. 10 ). 110 The LC 50 value determined for HDF cells is 10000 ppb for C 3 , 40000 ppb for Na
ð2À3ÞÀ and > 5 000 000 ppb for C 60 (OH) 24 .
Toxicity of pristine fullerenes against human and murine macrophages was assessed by measuring the amount of nitric oxide (NO) released upon exposure to nano-C 60 . Murine macrophages (J774), stimulated by lipopolysaccharide (LPS), incubated for 24 h, 48 h and 72 h with nano-C 60 at various concentrations (15 g/mL, 30 g/mL and 60 g/mL) showed no signi¯cant increases in NO release (compared to LPS stimulated positive controls). 111 Use of nano-C 60 suspensions did not induce signi¯cant toxicity in human monocyte derived macrophages (MDMs) at similar treatment concentrations after 1 h, 24 h and 48 h of incubation. Compared to macrophages treated with graphite and single walled carbon nanotubes, exposure to fullerenes did not induce formation of elongated microvilli-like structures and cell surface protrusions (see Fig. 11 ), suggesting the absence of macrophage activation and cellular damage.
Self-assembling supramolecular structures of amphiphilic fullerene dendrimers (AF-1, a.k.a. buckysomes) did not show any adverse e®ects on cellular proliferation or membrane integrity of macrophages, liver and kidney cells, compared to PBS treated controls when evaluated using MTT and LDH assays, for treatment concentrations ranging from 0.02À2 mg/mL AF-1. 96 Stable internalization of buckysomes in cells was observed by°u orescence microscopy. In another study, human epidermal keratinocyte (HEK) cells were incubated with fullerene-phenylalanine conjugates (fullerenebased amino acid complexes, Baa) at 0.4 mg/mL, 0.04 mg/mL and 0.004 mg/mL concentrations for 24 h and 48 h. 112 MTT assay results indicated a dose-dependent decrease in cell viability. Additionally, for 0.4 mg/mL and 0.04 mg/mL treatment groups, signi¯cant increases in the levels of proin-°a mmatory cytokines such as IL-1 and IL-6 along with cellular internalization of Baa were observed after 24 h of exposure.
In vitro studies assessing cytotoxicity and cellular internalization of fullerene derivatives such as [C 61 (CO 2 H) 2 ] in COS-7 cells, and nano-C 60 (OH) 22À26 in human retinal pigment epithelium (hRPE) and human lens epithelium (HLE 3-B) cells were also performed.
113À115 COS-7 cells were incubated with C 61 (CO 2 H) 2 (labeled with 14 C,10 M) for 24 h. Postincubation, cells were harvested using trypsinization, recovered using low-speed centrifugation (2000 g, 10 min) and homogenized. Cell lysate was subjected to di®erential centrifugation and followed by radioactive quanti¯cation. Maximum radioactivity was recorded from the mitochondrial fraction suggesting mitochondrial localization of C 61 (CO 2 H) 2 . In another study, intracellular accumulation and cytotoxicity ($ 25% cell viability) of hRPE cells was observed upon exposure to > 10 M nano-C 60 (OH) 22À26 concentrations upon culture in the presence of light (8.5 J cm À2 ). 115 However, in the absence of light, $ 80% cell viability was observed up to 50 M treatment concentrations. Singlet oxygen measurements indicate that fullerenols produce singlet oxygen species upon exposure to light with a quantum yield of È ¼ 0:05 in D 2 O, suggesting that the observed cytotoxicity maybe a result of photodamage due to type I (free radical induced) or type II (singlet oxygen induced) mechanisms.
Hemolytic potential of various water-soluble fullerene derivatives was assessed by measuring hemoglobin release after 30 min of RBC exposure. 116 Results indicate that bis-functionalized fullerene derivatives (possessing carboxylic acid groups or one cationic chain) did not induce hemolysis up to treatment concentrations of 80 M whereas derivatives with two cationic chains induced $ 40À50% hemolysis at treatment concentrations ranging between 20À60 M. Further, cytotoxicity of fullerene derivatives was assessed using Hep-G2, LLC-PK 1 and MCF-7 cell lines and MTT assay. Cationic fullerene derivatives exhibited signi¯cant cytotoxicity against all cell lines with LD 50 values ranging between 1 M and 20 M whereas anionic or neutral derivatives did not induce any cytotoxic response with LD 50 values > 80 M for all cell lines.
In vivo toxicity, and biodistribution

Oral administration
Biodistribution of water-soluble radiolabeled fullerenes ( 14 C), examined after 160 h of oral exposure in mice showed clearance via feces within 48 h of administration. 117 However, trace amounts were observed in urine, suggesting that fullerenes possess the ability to pass through mice gut walls. Oral administration of water-soluble polyalkylsulfonated fullerenes to rats (n ¼ 6, two regimens: 50 mg/kg single dose and 50 mg/kg daily for 12 days) was nontoxic. 118 Compared to healthy animals, suppression of liver cytochrome P-450, cytochrome b5 and benzo(a)pyrene hydroxylase (liver marker enzyme) were observed. The LD 50 value for polyalkylsulfonated C 60 was 50 mg/kg. In an acute toxicity study, fullerite (mixture of C 60 and C 70 Þ was administered to male and female Sprague Dawley rats at high concentrations (2000 mg/kg) for 15 days. 119 This treatment resulted in survival of all animals with normal weight gain (compared to healthy controls, 0 mg/kg fullerite administration).
Dermal exposure
Toxicity studies using dermal exposure are important because of the use of fullerenes in cosmetics as anti-wrinkle, anti-aging and skin-whitening agents. 120 Skin penetrating ability of fullerenes is dependent on the solvent phase used for dispersion. In comparison to mineral oil, determined by transmission electron microscopy, fullerenes dispersed in chloroform, toluene and cyclohexane were localized in the stratum corneum of pigs after 4 days of application (200 g/mL, 500 L). 121 In another study, C 60 suspensions using squalane (LF-SQ) as the dispersing agent showed dermal penetration at high exposure concentrations (223 ppm in LF-SQ). 122 Interestingly, dermal penetration was absent at lower exposure concentrations (2.23 ppm and 22.3 ppm), suggesting that fullerene penetration through the epidermis is concentration dependent. Mechanical compression and skin°exion increased passive diffusion of fullerenes through epidermis. 100 In another study, 30 volunteers were exposed to a patch of Whatmann¯lter paper (No. 3) saturated with watersoluble fullerenes. 123 The results show absence of skin irritation and allergies after 96 h of exposure, suggesting that fullerenes do not induce acute toxic response in skin. However, long-term toxicity studies need to be performed for a proper understanding of fullerene toxicity via dermal exposure.
Intraperitoneal and intravenous administration
Toxicity of C 60 -PEG conjugates administered intraperitoneally in tumor bearing mice was evaluated using body weight as a marker after 15 days of injections. 88 At low treatment concentrations (1.8À 180 mg/kg injections), normal weight gain was observed in treatment groups compared to the control group (no injection). However, transient weight loss was observed for groups treated with higher concentrations of PEG-C 60 conjugate (1800 mg/kg). Liver marker enzymes such as glutamic pyruvic transaminase (GPT) and glutamate oxaloacetate transaminase (GOT) were present at physiological levels for groups with > 1 mg/kg injections of C 60 -PEG conjugates. Indicators of nephrotoxicity such as blood urea nitrogen (BUN), GOT and GPT were present at normal physiological levels (BUN ¼ 20: 18 ] was administered to mice via intraperitoneal injections (0.5 g/kg and 1 g/kg dose). 124 Animals receiving 0.5 g/kg and 1 g/kg dose of fullerenol showed reductions in liver marker enzymes such as cytochrome b5, NADPH-cytochrome P450, benzo(a)pyrene hydroxylase and aniline hydroxylase, compared to animals receiving 0.01 g/kg and 0.1 g/kg dose. The LD 50 value of fullerenol was estimated to be 1.2 g/kg. In another study, e®ects of pretreatment with C 60 on acute carbon tetrachloride intoxication in rats were studied. In comparison to animals with CCl 4 intoxication and no fullerene administration, histopathological examinations show the absence of liver¯brosis and in-°a mmation in rats injected with pristine fullerenes (2 g/kg, single dose). 125 Furthermore, physiological levels of alanine aminotransferase ($100 IU/L) were observed suggesting the absence of liver damage due to fullerene administration.
Polyalkylsulfonated fullerene [C 60 ((CH 2 Þ 4 SO 3 Na) 4À6 ], administered intraperitoneally in rats at sub-acute (60 mg/kg, 12 days) and acute (1000 mg/ kg, 24 h) levels resulted in death of 5 animals (out of 6) at 750 mg/kg and all animals at 1000 mg/kg within 24 h of injections. 118 Although elimination of [C 60 ((CH 2 Þ 4 SO 3 Na) 4À6 ] was observed via urine and feces, accumulation was observed in liver and spleen macrophages, along with suppression of cytochrome P450 activity. Note, that such an acute toxicity response was limited to animals receiving high doses of fullerenes (1000 mg/kg), and was not observed for lower treatment doses. In another study, a bis (monosuccinimide) derivative of p p'-bis(2-aminoethyl-diphenyl C 60 Þ, MSAD-C 60 , did not elicit acute toxicity (100% survival) when administered at 15 mg/kg to Sprague-Dawley rats. 126 At high treatment concentrations (25 mg/kg dose), shortness of breath, violent movements and eventual death was observed within 5 min of injections.
Pulmonary administration (inhalation)
Water-based suspensions of C 60 (OH) 24 and nano-C 60 were administered via intratracheal instillation to mice at 0.2 mg/kg, 0.4 mg/kg, 1.5 mg/kg or 3 mg/ kg doses for 1 day to 3 months. 127 Normal physiological levels of alkaline phosphatase (60À120 IU/ L), lactate dehydrogenase (50À75 IU/L) and neutrophils (1À5% of total cell count) (total cell count ¼ 5 Â 10 6 À7:5 Â 10 6 cells) were observed in bronchoalveolar lavage°uid (BAL) after 24 h of administration. On the contrary, positive controls showed a persistent increase in the number of neutrophils (20À50% of total cell count), eventually leading to an increase in lung weight due to parenchymal lung cell proliferation. Furthermore, nano-C 60 resulted in increased lipid peroxidases levels ($ 100% increase compared to controls administered with water) in a dose-dependent manner. Lung in°ammation and¯brosis observed in positive controls (see Fig. 12 ), were absent in nano-C 60 and C 60 (OH) 24 treated groups (3 mg/kg treatment for 3 months), indicating the absence of nano-C 60 and C 60 (OH) 24 toxicity, contradictory to previous reports. . 128 Compared to healthy controls, rats administered with C 60 nanoparticles showed a minimal decrease in RBC ($ 2:7%), hemoglobin ($ 2:9%) and packed cell volume ($ 2:6%) in the nanoparticle-exposed group. However, rats exposed to C 60 microparticles showed decreases in white blood cells ($ 20:9%), monocytes ($ 72%), eosinophils ($ 45%) and platelets ($ 13%). In comparison to healthy controls, rats exposed to C 60 nanoparticles also showed minimally increased blood glucose levels ($ 3:5%), while rats exposed to C 60 microparticles showed increases in bile acids ($ 55%), creatinine kinase ($ 33%) and decreased albumin concentration ($ 2%). Macrophages from both exposure groups contained brown pigments corresponding to intracellular localization of C 60 . Lung half-lives for C 60 micro and nanoparticles were 29 and 26 days, respectively. The lung deposition rate and deposition fraction were 50% and 41% higher in animals administered C 60 nanoparticle compared to animals receiving C 60 microparticles.
In another study, C 60 -PBS suspensions (single exposure, 0.05 mL) administered via intratracheal instillation to female ICR mice at a¯nal treatment concentration of 625 g (euthanized after 0 min and 5 min of instillation) or 1000 g (euthanized after 1 h, 6 h, 24 h, or 7 days after instillation) resulted in elevated levels of C 60 in the circulation. 129 Capillary lumens of pulmonary lymph nodes and lungs were lined with aggregates of fullerenes and intracellular accumulation of fullerenes in alveolar endothelial and epithelial cells (via pinocytosis) was observed by transmission electron microscopy imaging. These results suggest that fullerenes have the potential to permeate the air-blood barrier (ABB) and can be used to administered therapeutics to organs via blood circulation. These¯ndings may not apply to human exposure, as studies with mammalian species do not report any fullerene translocation to blood circulation via ABB.
Several studies assessing the genotoxicity and reproductive toxicity of fullerenes do not show any adverse e®ects. 119, 130, 131 However, for a complete understanding of reproductive toxicity, additional toxicity studies assessing the developmental e®ects of fullerenes must be performed. 132, 133 In general, negligible in vitro and in vivo (mainly in small animal such as mice or rats) toxicity of watersoluble fullerene derivatives as determined by various cell culture and animal studies may not be su±cient to answer all concerns related to fullerene toxicity. Additional dose and time-dependent toxicity and pharmacology studies in other animal models (preferably a large animal model), using the various methods of administration, are necessary. is an anti-aging, anti-wrinkle skin cream utilizing the antioxidant properties of fullerenes to reduce free radical induced damage in skin. Progress toward development of fullerene or metallofullerenebased products for in vivo biomedical applications has been slow or has stalled. All the research and development work on these products to date has been at the preclinical stage. C-Sixty Inc. (now a subsidiary of Arrowhead Research Corporation, Toronto, Canada) is developing fullerene-based drugs for AIDS and neurodegenerative diseases such as Parkinson's, Alzheimer's and ALS (Lou Gehrig's disease) with several products under preclinical investigations. 134 Luna nanoworks Inc. (division of Luna Innovations Inc., Danville, VA, USA) is developing metallofullerenes for diagnostic applications. Their products, such as Trimetaspherer and Hydrochalaroner are derivatives of metallofullerenes encapsulating three gadolinium ions (Gd 3 N@C 60 Þ, are currently under preclinical investigation as MRI contrast agents.
Summary and Future Perspective
Studies to date clearly demonstrate the multifunctional capabilities of fullerenes and metallofullerenes for diagnostic and therapeutic uses. Despite signi¯cant progress, in vivo toxicity and biodistribution of fullerenes and metallofullerenes is not yet thoroughly understood. There is an emerging consensus that in vivo toxicity of these carbon nanoparticles is not only dose and time-dependent, but also depends on a number of other factors such as: type (e.g., C 60 , C 70 , M@C 60 , M@C 82 Þ, functional groups used to water solubilize these nanoparticles (e.g., ÀOH, ÀCOOH), and method of administration (e.g., intravenous, intraperitoneal). Therefore, pharmacology of every new fullerene-or metallofullerene-based complex must be assessed individually as a di®erent compound. Additionally, costs and time constraints associated with fullerene production and processing (puri¯cation and sorting) are barriers for some applications. However, these costs are highly dependent on the speci¯c application. In recent years, the focus has shifted toward investigating the potential of other carbon nanoparticles such as carbon nanotubes and graphene for biomedical applications. These shifts negatively impacted biomedical research using fullerenes and metallofullerenes resulting in decreased numbers of scienti¯c publications about these nanoparticles. Nevertheless, harnessing the multifunctional capabilities of fullerene-and metallofullerene-based compounds toward the development of biomedical technologies represents a challenging, but potentially rewarding opportunity towards the development of next-generation biomedical products.
